Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study

  • O. Abdel-RahmanEmail author
Brief Research Article



To clarify the prognostic role of human papilloma virus (HPV) status among patients with hypopharyngeal carcinoma.


Surveillance, Epidemiology and End Results (SEER) HPV head and neck cancer database has been accessed and cases with hypopharyngeal squamous cell carcinoma with known HPV status were retrieved. Kaplan–Meier survival estimates were used to evaluate the impact of HPV status on overall survival outcomes of included patients and multivariable cox regression analysis was used to assess the impact of HPV status on overall and head and neck cancer-specific survival.


A total of 1157 patients’ records with hypopharyngeal carcinoma were included in the current analysis. Using Kaplan–Meier survival estimates, patients with HPV positive status seem to have better overall survival compared to patients with HPV negative status (P < 0.01). When stratified by stage, patients with HPV positive regional and distant disease have better overall survival compared to patients with HPV negative regional and distant disease (P < 0.01 for both categories). The same observation cannot be confirmed for patients with localized disease (P = 0.15). Using multivariable Cox regression analysis, HPV positive status seems to be associated with better overall survival (HR for HPV negative versus HPV positive status: 1.76; 95% CI 1.39–2.24; P < 0.01) and cancer-specific survival (HR for HPV negative versus HPV positive status: 1.54; 95% CI 1.12–2.11; P < 0.01).


Patients with HPV positive hypopharyngeal carcinoma seem to have better overall and cancer-specific survival compared to patients with HPV negative hypopharyngeal carcinoma.


HPV Head and neck cancer Hypopharyngeal carcinoma Prognosis 



This study is based on the SEER HPV head and neck cancer database.

Compliance with ethical standards

Conflict of interest

I have no conflicts of interest.

Research involving human participants and/or animals

This work does not involve human participants or animals.

Informed consent

This work is based on secondary analysis of publicly available dataset. Informed consent was not required.

Supplementary material

12094_2020_2289_MOESM1_ESM.docx (16 kb)
Supplementary file1 (DOCX 16 kb)


  1. 1.
    Rettig EM, D'Souza G. Epidemiology of head and neck cancer. Surg Oncol Clin N Am. 2015;24(3):379–96.CrossRefGoogle Scholar
  2. 2.
    Cole L, Polfus L, Peters ES. Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995–2005. PLoS ONE ONE. 2012;7(3):e32657.CrossRefGoogle Scholar
  3. 3.
    Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014;50(5):380–6.CrossRefGoogle Scholar
  4. 4.
    Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer. 2017;123(9):1566–75.CrossRefGoogle Scholar
  5. 5.
    Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer. J Natl Cancer Inst. 2015;107(12):djv344.CrossRefGoogle Scholar
  6. 6.
    Heath S, Willis V, Allan K, Purdie K, Harwood C, Shields P, et al. Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice. Clin Oncol (R Coll Radiol). 2012;24(1):e18–23.CrossRefGoogle Scholar
  7. 7.
    Bates JE, Morris CG, Hitchcock KE, Dziegielewski PT, Mendenhall WM, Amdur RJ. Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status. Radiother Oncol. 2019;140:6–9.CrossRefGoogle Scholar
  8. 8.
  9. 9.
    Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.CrossRefGoogle Scholar
  10. 10.
    Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9.CrossRefGoogle Scholar
  11. 11.
    Melkane AE, Auperin A, Saulnier P, Lacroix L, Vielh P, Casiraghi O, et al. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. Head Neck. 2014;36(2):257–65.CrossRefGoogle Scholar
  12. 12.
    Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60.CrossRefGoogle Scholar
  13. 13.
    Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50.CrossRefGoogle Scholar
  14. 14.
    O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51.CrossRefGoogle Scholar
  15. 15.
    Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 2015;33(8):836–45.CrossRefGoogle Scholar
  16. 16.
    Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7–28.CrossRefGoogle Scholar
  17. 17.
    Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36(3):262–7.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2020

Authors and Affiliations

  1. 1.Department of Oncology, Cross Cancer InstituteUniversity of AlbertaEdmontonCanada

Personalised recommendations